Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.94 [0.57, 1.54]9 studies · 1489 participantsModerate